세계 바이오마커 시장 : 규모, 점유율, 동향 분석 보고서 - 유형별, 제품별, 용도별, 질환별, 지역별, 부문별 예측(2024-2030년)

Biomarkers Market Size, Share & Trends Analysis Report By Type (Efficacy, Validation), By Product, By Application (Drug Discovery & Development, Personalized Medicine), By Disease, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,443,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,862,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,700,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

바이오마커 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 바이오마커 세계 시장 규모는 2024년부터 2030년에 걸쳐 복합 연간 성장률(CAGR) 13.36%를 기록할 것으로 예측되며, 2030년에는 1,942억 1,000만 달러에 이를 전망입니다.

제약기업이나 바이오테크놀러지 기업에 의한 R&D 투자 증가, CRO(의약품개발업무수탁기관) 증가, 신흥국에서의 임상시험 비용의 저하가 업계의 주요 촉진요인이 되고 있습니다. 또한 주요 기업은 생산 능력을 높이고 제품 제공의 아웃리치를 촉진하기 위해 다양한 전략을 활용하고 있습니다. 2022년 6월, Paige는 얀센과의 제휴를 발표하고, 얀센이 개발한(H&E) 기반의(AI) 탑재 바이오마커 검사로 방광암 환자에서 실용적인 FGFR3 및 FGFR2의 게놈 변화를 선별 가능성을 평가합니다.

암, 당뇨병, 심혈관 장애 등 만성 질환의 유병률 증가는 업계 성장을 가속할 것으로 예상됩니다. 미국암협회에 따르면 2022년에는 미국에서 추정 190만명의 암 환자가 새롭게 등록되어 609,360명이 사망했습니다. 세계에서 가장 많은 것은 유방암과 폐암입니다. 게다가 2020년에 Institute for Health Metrics and Evaluation이 발표한 보고서에 따르면, 심혈관 질환은 연간 약 1,890만 명의 사망을 일으킵니다. 새로운 진단 바이오마커의 식별에 초점을 맞춘 설문 조사 증가는 업계의 성장을 뒷받침하고 있습니다. 예를 들어(2022년) 2월 일본 과학자들은 악성 흉막 중피종에 적응하는 2개의 새로운 진단 조직 바이오마커인 PHGDH와 TRIM29를 발견했습니다.

이 약물은 중피종의 신속한 진단에 사용될 수 있으며 의사가 중피종과 다른 암을 구별하는 데 도움이 됩니다. 게다가 2020년 1월에는 Journal of Nuclear Medicine 잡지에 게재된 신진 조사 연구가 여러 유방암 바이오마커의 가능성에 대해 논하고 있습니다. 이 연구에서 인식된 주목할 만한 식별하기 쉬운 이미지 바이오마커는 18F-FDG PET였습니다. 또한, COVID-19의 대유행은 질병의 발견과 치료를 촉진하기 위해 바이오 마커의 사용을 장려합니다. 예를 들어, 2021년 3월 Tiger Tech COVID Plus Monitor로 명명된 새로운 바이오마커 기반 스크리닝 장치가 미국 FDA에 의해 승인되었습니다.

이 장치는 5세 이상의 COVID-19 및 기타 응고 항진 및 염증성 질환의 바이오마커 확인에 사용할 수 있습니다. 또한 주요 진출기업의 다양한 전략적 이니셔티브가 수요를 충족시킬 것으로 예상됩니다. 예를 들어(2022년) 8월, 로슈는 머크의 면역요법 키트루다에 의한 치료 대상인 pMMR 자궁내막암 환자 및 dMMR 고형암 환자를 검출하기 위한 벤타나 MMR RxDx 패널의 미국 FDA 승인을 취득 했습니다. 이번 VENTANA MMR RxDx Panel의 승인은 이 회사가 최근 출시한 패널의 라벨 확대입니다. 또한 2021년 12월, Siemens Healthineers는 Freeome과 제휴하여 회사의 기존 이미징 기술을 확장하기 위해 조기 유방암 검출에 적합한 새로운 마커를 확인했습니다.

바이오마커 시장 보고서 하이라이트

• 안전 부문은 2023년 37.62%의 최대 판매 점유율을 창출 및 약물 개발에서 안전성 바이오마커의 채택 증가로 점유했습니다.
• 효능 바이오마커 분야는 연구활동 촉진을 위한 전략적 공동연구 증가로 2024년부터 2030년까지 가장 빠른 복합 연간 성장률(CAGR)을 나타낼 전망입니다.
• 창약,개발 분야는 시장 진출기업에 의한 광범위한 조사개발 노력과 창약에 있어서의 바이오마커의 채용 증가에 의해 2023년 시장을 독점했습니다.
• 암 분야는 2023년에 시장을 선도해 2024년부터 2030년까지 그 우위성을 유지할 것으로 예측됩니다. 그러나, 신경 질환 분야는 예측 기간 동안 가장 빠른 복합 연간 성장률(CAGR)을 기록할 것으로 예측됩니다.
• 아시아태평양은 2024년부터 2030년까지 가장 빠른 복합 연간 성장률(CAGR)을 달성할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 바이오마커 시장 : 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 시장 기회 분석
  • 시장 과제 분석
• 바이오마커 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • 가격 분석

제4장 바이오마커 시장 : 유형의 추정,동향 분석

• 유형 시장 점유율(2023년,2030년)
• 부문 대시보드
• 유형별 세계 바이오마커 시장 전망
• 시장 규모, 예측 및 동향 분석(2018년-2030년)

제5장 바이오마커 시장 : 제품의 추정,동향 분석

• 제품 시장 점유율(2023년,2030년)
• 부문 대시보드
• 제품별 세계 바이오마커 시장 전망
• 시장 규모, 예측 및 동향 분석(2018년-2030년)

제6장 바이오마커 시장 : 용도의 추정,동향 분석

• 용도 시장 점유율(2023년,2030년)
• 부문 대시보드
• 용도별 세계 바이오마커 시장 전망
• 시장 규모, 예측 및 동향 분석(2018년-2030년)

제7장 바이오마커 시장 : 질환의 추정,동향 분석

• 질병 시장 점유율(2023년,2030년)
• 부문 대시보드
• 질병별 세계 바이오마커 시장 전망
• 시장 규모, 예측 및 동향 분석(2018년-2030년)

제8장 바이오마커 시장 :지역의 추정,동향 분석

• 지역 시장 점유율 분석(2023년,2030년)
• 지역 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모와 예측 동향 분석(2018년-2030년)
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 주요 시장 진출기업별 최근의 동향과 영향 분석
• 회사/경쟁의 분류
• 벤더 상황
  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Epigenomics AG
  • General Electric
  • Johnson &Johnson Services, Inc.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • QIAGEN
  • Merck KGaA
  • PerkinElmer Inc.
  • Agilent Technologies, Inc.
  • Eurofins Scientific

BJH

영문 목차

영문목차

Biomarkers Market Growth & Trends:

The global biomarkers market size is expected to reach USD 194.21 billion by 2030, registering a CAGR of 13.36% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising R&D investments by pharmaceutical and biotechnology companies, increasing number of Contract Research Organizations(CROs), and declining cost of clinical trials in emerging economies are the major driving factors for the industry. In addition, key players leverage various strategies to increase their production capabilities and promote the outreach of their product offerings. In June 2022, Paige announced its collaboration with Janssen to evaluate the potential of an (H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder cancer.

The increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders is anticipated to fuel industry growth. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases were registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. In addition, according to a report published in 2020 by the Institute for Health Metrics and Evaluation, cardiovascular diseases cause about 18.9 million deaths annually. Increasing research focused on the identification of new diagnostic biomarkers is fueling the industry's growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma.

These agents can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers. Moreover, in January 2020, a nascent research study published in the Journal of Nuclear Medicine discussed the potential of several breast cancer biomarkers. A notable and easily identifiable imaging biomarker recognized in the study was 18F-FDG PET. Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for facilitating the detection & treatment of the disease. For instance, in March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus Monitor, was approved by the U.S. FDA.

The device can be used for the identification of biomarkers for COVID-19 and other hypercoagulable & hyperinflammatory conditions in individuals aged 5 years & above. Furthermore, various strategic initiatives undertaken by leading participants are anticipated to cater to demand. For instance, in August 2022, Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR endometrial cancer patients and dMMR solid tumor patients eligible for treatment with Merck's immunotherapy Keytruda. This approval for the VENTANA MMR RxDx Panel is a label expansion of the company's recent on-market panel. Also, in December 2021, Siemens Healthineers partnered with Freenome to identify novel suitable markers for the detection of early breast cancer to expand its existing imaging technologies.

Biomarkers Market Report Highlights:

• The safety segment held the largest revenue share of 37.62% in 2023 owing to the increased adoption of safety biomarkers in drug discovery and development
• The efficacy biomarkers segment is expected to grow at the fastest CAGR from 2024 to 2030 due to a rise in strategic collaborations for promoting research activities
• The drug discovery & development segment dominated the market in 2023 due to the extensive R&D efforts taken by leading participants, and the rising adoption of biomarkers in drug discovery
• The cancer segment led the market in 2023 and is expected to retain its dominance from 2024 to 2030. . However, the neurological diseases segment is anticipated to record the fastest CAGR over the forecast years
• Asia Pacific is anticipated to attain the fastest CAGR from 2024 to 2030 due to the rising investments by key players and increasing disease prevalence in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Product
  • 1.2.3. Application
  • 1.2.4. Disease
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for Primary Interviews in North America
    • 1.4.5.2. Data for Primary Interviews in Europe
    • 1.4.5.3. Data for Primary Interviews in Asia Pacific
    • 1.4.5.4. Data for Primary Interviews in Latin America
    • 1.4.5.5. Data for Primary Interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type and product outlook
  • 2.2.2. Application and disease outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing funding for biomarkers
    • 3.2.1.2. Increasing prevalence for chronic diseases
    • 3.2.1.3. Technological advancement
    • 3.2.1.4. Growing importance of companion diagnostics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of reimbursement policies for biomarkers
    • 3.2.2.2. High capital investment and lengthy timelines for biomarker development
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Emergence of personalized medicine
    • 3.2.3.2. Emerging economies
  • 3.2.4. Market challenge analysis
    • 3.2.4.1. Challenges associated with biomarkers validation
    • 3.2.4.2. Technical issues related to sample collection and storage
• 3.3. Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
    • 3.3.3.1. Selling price of biomarker by top players

Chapter 4. Biomarkers Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Biomarkers Market by Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Safety biomarkers
    • 4.4.1.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Efficacy biomarkers
    • 4.4.2.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Predictive biomarkers
    • 4.4.3.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Surrogate biomarkers
    • 4.4.4.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Pharmacodynamic biomarkers
    • 4.4.5.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. Prognostics biomarkers
    • 4.4.6.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.7. Validation biomarkers
    • 4.4.7.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Biomarkers Market: Product Estimates & Trend Analysis

• 5.1. Product Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Biomarkers Market by Product Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Consumables
    • 5.4.1.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. Services
    • 5.4.2.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.3. Software
    • 5.4.3.1. Software market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Biomarkers Market: Application Estimates & Trend Analysis

• 6.1. Application Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Biomarkers Market by Application Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Diagnostics
    • 6.4.1.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.2. Drug Discovery and Development
    • 6.4.2.1. Drug discovery and development market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.3. Personalized Medicine
    • 6.4.3.1. Personalized medicine market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.4. Disease Risk Assessment
    • 6.4.4.1. Disease risk assessment market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.5. Others
    • 6.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Biomarkers Market: Disease Estimates & Trend Analysis

• 7.1. Disease Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Biomarkers Market by Disease Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Cancer
    • 7.4.1.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.2. Safety biomarkers
    • 7.4.1.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.3. Efficacy biomarkers
    • 7.4.1.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.4. Predictive biomarkers
    • 7.4.1.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.5. Surrogate biomarkers
    • 7.4.1.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.6. Pharmacodynamic biomarkers
    • 7.4.1.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.7. Prognostics biomarkers
    • 7.4.1.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.1.8. Validation biomarkers
    • 7.4.1.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.2. Cardiovascular Diseases
    • 7.4.2.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.2. Safety biomarkers
    • 7.4.2.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.3. Efficacy biomarkers
    • 7.4.2.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.4. Predictive biomarkers
    • 7.4.2.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.5. Surrogate biomarkers
    • 7.4.2.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.6. Pharmacodynamic biomarkers
    • 7.4.2.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.7. Prognostics biomarkers
    • 7.4.2.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2.8. Validation biomarkers
    • 7.4.2.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)Neurological Diseases
    • 7.4.3.1. Neurological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.2. Safety biomarkers
    • 7.4.3.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.3. Efficacy biomarkers
    • 7.4.3.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.4. Predictive biomarkers
    • 7.4.3.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.5. Surrogate biomarkers
    • 7.4.3.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.6. Pharmacodynamic biomarkers
    • 7.4.3.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.7. Prognostics biomarkers
    • 7.4.3.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3.8. Validation biomarkers
    • 7.4.3.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.4. Immunological Diseases
    • 7.4.4.1. Immunological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.2. Safety biomarkers
    • 7.4.4.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.3. Efficacy biomarkers
    • 7.4.4.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.4. Predictive biomarkers
    • 7.4.4.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.5. Surrogate biomarkers
    • 7.4.4.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.6. Pharmacodynamic biomarkers
    • 7.4.4.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.7. Prognostics biomarkers
    • 7.4.4.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4.8. Validation biomarkers
    • 7.4.4.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.5. Others
    • 7.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.2. Safety biomarkers
    • 7.4.5.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.3. Efficacy biomarkers
    • 7.4.5.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.4. Predictive biomarkers
    • 7.4.5.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.5. Surrogate biomarkers
    • 7.4.5.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.6. Pharmacodynamic biomarkers
    • 7.4.5.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.7. Prognostics biomarkers
    • 7.4.5.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5.8. Validation biomarkers
    • 7.4.5.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Biomarkers Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.8.2. Mexico
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ reimbursement structure
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key Country Dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts for 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. F. Hoffmann-La Roche Ltd.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Abbott
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Epigenomics AG
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. General Electric
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Johnson & Johnson Services, Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Thermo Fisher Scientific Inc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Bio-Rad Laboratories, Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Siemens Healthineers AG
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. QIAGEN
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Merck KGaA
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. PerkinElmer Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Agilent Technologies, Inc.
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. Eurofins Scientific
    • 9.3.16.1. Company overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Product benchmarking
    • 9.3.16.4. Strategic initiatives

관련자료